HPS-068 - Safety of JAK and TNF inhibitors in rheumatoid arthritis: A systematic review and meta-analysis of real-world evidence

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: HPS-068
• By: LIN, Hsin-Chung (Department of Pharmacy Practice, Tri-Service General Hospital, Taiwan China)
• Co-author(s): Mr Hsin-Chung Lin (Department of Pharmacy Practice, Tri-Service General Hospital, Taipei, Taiwan China)
  Mr Jen-Hsueh Shan (Department of Pharmacy Practice, Tri-Service General Hospital, Taipei, Taiwan China)
  Dr Chiu-Lan Yan (Department of Pharmacy, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan China)
  
• Abstract:

  Introduction：
  In 2022, "ORAL Surveillance" trial demonstrated that tofacitinib might increase the risk of major adverse cardiovascular events (MACEs) and malignancies compared to Tumor necrosis factor (TNF) inhibitors in rheumatoid arthritis (RA) patients aged ≥50 years old with at least one cardiovascular risk factor. Higher risks were observed ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login